

# Clinical Inertia and 2-Year Glycaemic Trajectories in Patients with Non-Newly Diagnosed Type 2 Diabetes Mellitus in Primary Care: A Retrospective Cohort Study

Ling-Wang An<sup>1</sup>Xiang-Lan Li<sup>1</sup>Lin-Hui Chen<sup>2</sup>Hong Tang<sup>3</sup>Qun Yuan<sup>4</sup>Yan-Jun Liu<sup>5</sup>Yu Ji<sup>6</sup>Ju-Ming Lu<sup>1,7</sup>

<sup>1</sup>Department of Endocrinology, Beijing Ruijing Diabetes Hospital, Beijing, 100079, People's Republic of China;

<sup>2</sup>Department of Endocrinology, Taiyuan Diabetes Hospital, Taiyuan, 030013, People's Republic of China; <sup>3</sup>Department of Share-Care Center, Chengdu Ruian Diabetes Hospital, Chengdu, 610000, People's Republic of China; <sup>4</sup>Department of Endocrinology, Heilongjiang Ruijing Diabetes Hospital, Harbin, 150009, People's Republic of China; <sup>5</sup>Department of Endocrinology, Lanzhou Ruijing Diabetes Hospital, Lanzhou, 730000, People's Republic of China; <sup>6</sup>Department of Endocrinology, Beijing Aerospace General Hospital, Beijing, 100076, People's Republic of China; <sup>7</sup>Department of Endocrinology, The General Hospital of the People's Liberation Army, Beijing, 100853, People's Republic of China

**Objective:** To analyse diabetes treatment, treatment change and self-management behaviours in association with 2-year glycaemic trajectories in patients with non-newly diagnosed type 2 diabetes mellitus in Chinese primary care.

**Methods:** This was an observational, multi-centre, longitudinal, retrospective cohort study. Clinical data of 4690 subjects were extracted from electronic medical records, including serial glycated haemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) measurements, antidiabetic medication records and compliance to exercise, diet, medications and self-monitoring of blood glucose (SMBG). Patterns of longitudinal HbA<sub>1c</sub> trajectories were identified using the percentage of HbA<sub>1c</sub> measurements <7.5% from the second available HbA<sub>1c</sub> measurement. Clinical relevance of the clusters was assessed through multivariable analysis.

**Results:** Approximately half of the participants demonstrated good glycaemic control; of these, 34.5% demonstrated stable, good control, and 13.7% demonstrated relatively good control. About 16.2% demonstrated moderate control, and 35.6% demonstrated poor control. From the good to poor control groups, the percentage of subjects treated with insulin at baseline and during the follow-up period increased gradually, while the percentage of subjects adhering to exercise, diet, medications and SMBG decreased gradually. Compared with baseline, the adherence to exercise, diet, medications and SMBG improved significantly. Approximately 50% and 26% of subjects in the two poorest control groups, respectively, experienced treatment changes. After multivariable adjustments, baseline HbA<sub>1c</sub>  $\geq 7.5\%$ , HbA<sub>1c</sub> change  $\geq -0.5\%$  from baseline to visit 1, insulin treatment, treatment change, poor adherence to diet, exercise, SMBG during the follow-up period and HbA<sub>1c</sub> measurements  $< 3$  per year were significantly associated with poorer glycaemic control.

**Conclusion:** We identified four longitudinal HbA<sub>1c</sub> trajectories in patients with non-newly diagnosed type 2 diabetes. Even if baseline HbA<sub>1c</sub> is suboptimal, aggressive treatment changes, good adherence during the follow-up period,  $\geq 3$  HbA<sub>1c</sub> measurements per year and reducing HbA<sub>1c</sub> levels to a certain extent by the first follow-up visit were important for good, stable, long-term glycaemic control.

**Keywords:** haemoglobin A<sub>1c</sub>, self-monitoring of blood glucose, diabetes, glycaemic trajectories, glycaemic control

Correspondence: Ju-Ming Lu  
Department of Endocrinology, The General Hospital of the People's Liberation Army, No. 28 of Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China  
Tel +86 10 8822 9999  
Email lujm666\_l@21cn.com

## Introduction

The difficulty of managing blood glucose levels lies in long-term blood glucose control, and glycated haemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) is often used to evaluate the effect of this. The serial measurements of HbA<sub>1c</sub> can form a trajectory that reflects the

long-term glycaemic control of diabetes for each patient. Previous analysis has suggested that HbA<sub>1c</sub> trajectories can be categorized into several distinct patterns.<sup>1</sup> Cumulative glycaemic exposure over time has also been used to categorise HbA<sub>1c</sub> trajectories.<sup>2</sup> The most commonly identified patterns were good, stable glycaemic control found in 56%–82.5% of patients with newly diagnosed type 2 diabetes and in 53.2% of patients with diabetes of a duration  $\geq 3$  years.<sup>3–6</sup> Patients may benefit from early good glycaemic control and be inclined to develop a long-term good, stable HbA<sub>1c</sub> trajectory thereafter. In McCoy's report, 95.5% of patients with stable, controlled diabetes kept a stable HbA<sub>1c</sub> trajectory during the follow-up period.<sup>7</sup> Unstable patterns identified included an increasing HbA<sub>1c</sub> trend, a decreasing HbA<sub>1c</sub> trend, stable moderate glycaemic control (eg HbA<sub>1c</sub> of 7.4%–7.8%) or stable, poor control (eg extremely high but stable HbA<sub>1c</sub> of 9.4%–10.2%).<sup>4–6</sup> All non-stable trajectories were associated with higher incidences of microvascular events.<sup>3</sup> In Rozing's report, an increase in HbA<sub>1c</sub> levels in the first year after diagnosis were associated with later diabetes-related morbidity and mortality, while an increase in HbA<sub>1c</sub> levels during the first six years after diagnosis was associated with later (6–19 years) microvascular complications.<sup>8</sup> Therefore, it is important to help patients achieve good glycaemic control in the first year after diagnosis or registration and keep it stable subsequently.

Two main reasons for suboptimal glycaemic control were identified in clinical practice: (1) patient non-adherence to prescribed treatment, and (2) clinical or therapeutic inertia, defined as the failure to start therapy or adhere to its intensification and non-intensification when appropriate.<sup>9,10</sup> The causes of clinical inertia included three classes of factors: (1) those related to the healthcare professionals (eg failure to set clear goals or to titrate treatment to achieve them); (2) those related to the patients (eg lifestyle factors, emotional or behavioural obstacles); (3) those related to the national healthcare system (eg no clinical guidelines, no disease register or team approach to care).<sup>10</sup>

There are few Chinese studies exploring the distinct long-term glycaemic trajectories and associated factors in patients with non-newly diagnosed type 2 diabetes in primary care. This retrospective cohort study aimed to investigate two aspects: (1) patterns of HbA<sub>1c</sub> trajectories shown as cumulative glycaemic exposure, as measured by repeated HbA<sub>1c</sub> values in follow-up tests  $\geq 12$  months after

registration/management; (2) risk factors for poor glycaemic control and clinical inertia originating from healthcare professionals (treatment titration) and patients (adherence to healthy diet, activity, self-monitoring of blood glucose [SMBG] and medications).

## Materials and Methods

### Settings and Data Source

In 2015, Ruijing Diabetes Chain Hospitals (RDCH, five primary care medical institutions in China) promoted a share-care model to improve diabetes management. From 2016, they used a share-care information system to collect and register information of people with diabetes. The demographic and clinical variables recorded in the database included age, gender, ethnicity, marital status, education, occupation, smoking status and alcohol consumption, diabetes type, family history, date of diagnosis, history of hypertension, dyslipidaemia, malignant neoplasms (all types), liver diseases (steatosis, hepatitis, cirrhosis), macrovascular complications (including ischaemic heart disease [angina, acute myocardial infarction, heart failure], stroke, transient ischaemic attack and peripheral arterial disease) and microvascular complications (including diabetic retinopathy, diabetic kidney disease [DKD] and diabetic neuropathy). Body mass index (BMI), blood pressure, blood lipid levels, HbA<sub>1c</sub>, self-management behaviours and medication information were also collected and recorded after registration. Patients were asked to check these parameters regularly according to Chinese guidelines during the follow-up visits and discuss them with their physicians for appropriate treatment titration. Patients received structured education from a nursing educator or dietitian from the share-care model management.

### Study Design

This was an observational, multi-centre, longitudinal, retrospective study based on medical records included in a diabetes share-care system database of the RDCH. All data were aggregated for each person after registration (to form a baseline) and during each follow-up visit. The analysis was based on individuals with a documented onset date of type 2 diabetes and clinical visits after diagnosis and during the follow-up period. This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Beijing Ruijing Diabetes Hospital. Due to the nature of the study (ie retrospective database searching), patient consent was not

required. We confirm that the data used in this article is anonymous or confidential.

## Study Population

For the present study, all those with type 2 diabetes aged 30–80 years and  $\geq 30$  years at the onset of diabetes were included. The inclusion criteria were: (1)  $\geq 3$  recorded HbA<sub>1c</sub> values during the follow-up period; (2) follow-up duration  $\geq 12$  months; (3) disease duration  $\geq 3$  years. Patients were excluded from the study if they had a history of type 1 diabetes, gestational diabetes and/or secondary diabetes, malignant tumour, serious liver (alanine aminotransferase  $\geq 3$  times normal upper limit) or kidney (estimated glomerular filtration rate  $< 30$  mL/min per  $1.73\text{ m}^2$ ) disease, dialysis, diabetic foot ulcer, were blind or had no medical records for baseline HbA<sub>1c</sub>, creatinine or BMI. The inclusion period extended from 1 January 2016 to 31 December 2019, with a minimum follow-up of 12 months per patient from the inclusion date. The final cohort comprised 4690 adults with non-newly diagnosed type 2 diabetes.

## Medication and Diabetes Self-Management Behaviours

Medication information for registration and follow-up visits was obtained. Treatment was categorised as therapy without insulin, therapy with insulin or combinations with oral antidiabetic drugs (such as metformin). Treatment must be adjusted in a timely manner when the blood glucose control is poor. Treatment change was defined as change in any treatment category in any of the follow-up visits compared with the registration day. Lack of change in antidiabetic treatment during the follow-up period was taken as clinical inertia originating from healthcare professionals.

Diabetes self-management behaviour information was collected according to the Chinese version of the diabetes self-care behaviour scale, including diet, exercise, SMBG and medication adherence in the previous seven days.<sup>11</sup> Good compliance was defined as following the health professionals' recommendations  $\geq 5$  days per week, including a healthy diet plan, exercise for at least 30 minutes a day, SMBG and use of prescribed antidiabetic medications. Poor adherence to healthy diet, activity, SMBG and the medication regime during the follow-up period was taken as clinical inertia originating from patients.

## Longitudinal HbA<sub>1c</sub> Measurements and Categories

HbA<sub>1c</sub> measurements were tested with high-performance liquid chromatography and standardized according to the Diabetes Control and Complications Trial.<sup>12</sup> Clinical measurements of HbA<sub>1c</sub> were obtained from the laboratory database from the time of cohort entry to the end of the follow-up period. Beginning with their second available HbA<sub>1c</sub> measurement, patients were categorized into four groups based on the percentage of HbA<sub>1c</sub> measurements  $< 7.5\%$ : Group 1 was  $\geq 90\%$  of HbA<sub>1c</sub> measurements  $< 7.5\%$ ; Group 2 was  $60\%–89\%$  of HbA<sub>1c</sub> measurements  $< 7.5\%$ ; Group 3 was  $30\%–59\%$  of HbA<sub>1c</sub> measurements  $< 7.5\%$ ; and Group 4 was  $< 30\%$  of HbA<sub>1c</sub> measurements  $< 7.5\%$ . The frequency of HbA<sub>1c</sub> measurements per year for each patient was calculated as the total number of HbA<sub>1c</sub> measurements divided by their total follow-up duration in years.

## Statistical Analysis

Patient characteristics were summarised using mean and standard deviation (SD), median and interquartile range (IQR), or number (percentage). Age, diabetes duration, BMI and HbA<sub>1c</sub> measurements are described by SD and IQR, and other indicators are described by  $n$  (%). After the normality test, patient characteristics of the four HbA<sub>1c</sub> subgroups were compared using the following tests: one-way analysis of variance tests for continuous variables with a normal distribution; Kruskal–Wallis' tests for continuous variables with a skewed distribution; and Pearson's Chi-squared tests for categorical variables. Multinomial logistic regression models were used to investigate which variables were associated with the respective HbA<sub>1c</sub> trajectory groups. Results are given as odds ratios with 95% confidence intervals. A two-sided  $P$  value of  $< 0.05$  was considered as statistically significant. All analyses were performed using SPSS Statistics 22.0.

## Results

### Patient Characteristics

The final analytic cohort comprised 4690 individuals (median age at cohort entry 61.75 years old; 52.8% male) (Table 1). The median duration of diabetes was 9.58 years (IQR 6.33–14.25 years), and the prevalence of diabetic retinopathy, diabetic kidney disease and neuropathy, as diagnosed,<sup>13–15</sup> at recruitment were 17.7%, 13.7% and 55.6%, respectively. The median follow-up time was 24.0 months (IQR 18.0–29.0 months) with 51.2% of

**Table 1** Demographic and Clinical Characteristics for the Overall Study Population and for the 4 Groups with Different Cumulative Glycaemic Exposures


Variables	n	Overall	Group 1	Group 2	Group 3	Group 4	Z $\chi^2$	P
<b>n (%)</b>		<b>4690 (100.0)</b>	<b>1616 (34.5)</b>	<b>642 (13.7)</b>	<b>761 (16.2)</b>	<b>1671 (35.6)</b>		
<b>Demographics</b>								
Age, years	4690	61.75 (55.83, 67.35)	62.00 (56.33, 67.33)	61.47±8.60	61.30±8.66	61.39±8.77	0.825	0.480
Sex (male) (n,%)		2475 (52.8)	873 (54.0)	338 (52.6)	402 (52.8)	862 (51.6)	1.962	0.580
Diabetes duration (years)	4690	9.58 (6.33, 14.25)	9.08 (5.75, 12.65)	9.33 (6.25, 13.50)*	9.83 (6.58, 14.33)**	10.42 (6.92, 15.25)**	68.744	0.000
≥10 (n,%)		2201 (46.9)	661 (40.9)	292 (45.5)*	365 (48.0)**	883 (52.8)**	47.887	0.000
Education (n,%)	4106						19.060	0.000
Below high school		2292 (55.8)	726 (51.3)	330 (59.0)**	368 (56.6)*	868 (58.6)**		
Above high school		1814 (44.2)	690 (48.7)	229 (41.0)	282 (43.4)	613 (41.4)		
<b>Comorbidities/complications</b>								
Hypertension (n,%)	4690	2682 (57.2)	891 (55.1)	383 (59.7)	465 (61.1)**	943 (56.4)	9.532	0.023
Dyslipidemia (n,%)	4690	3287 (70.1)	1103 (68.3)	460 (71.7)	539 (70.8)	1185 (70.9)	4.083	0.253
Hypercholesterolemia	4339	2883 (66.4)	925 (61.9)	398 (66.2)	491 (69.4)**	1069 (69.6)**	23.746	0.000
High triglyceridemia	4340	1956 (45.1)	589 (39.4)	282 (46.9)**	324 (45.8)**	761 (49.5)**	32.818	0.000
CVD (n,%)	4690	1146 (24.4)	374 (23.1)	171 (26.6)	187 (24.6)	414 (24.8)	3.256	0.354
PAD (n,%)	4690	1060 (22.6)	355 (22.0)	127 (19.8)	184 (24.2)	394 (23.6)	5.283	0.152
Retinopathy (n,%)	4690	831 (17.7)	203 (12.6)	104 (16.2)*	147 (19.3)**	377 (22.6)**	58.705	0.000
DKD (n,%)	4690	642 (13.7)	174 (10.8)	85 (13.2)	116 (15.2)**	267 (16.0)**	20.754	0.000
Neuropathy (n,%)	4690	2606 (55.6)	830 (51.4)	351 (54.7)	406 (53.4)	1019 (61.0)**	33.139	0.000
<b>Baseline characteristics</b>								
BMI (kg/m <sup>2</sup> )	4690	24.72 (22.89, 26.79)	24.64 (22.77, 26.64)	24.61 (23.03, 26.82)	24.65 (22.89, 26.79)	24.80 (23.03, 26.99)*	5.050	0.168
BMI (kg/m <sup>2</sup> ) (n,%)	4690						7.648	0.265
<24.0		1831 (39.0)	665 (41.2)	250 (38.9)	298 (39.2)	618 (37.0)*		
24.0~27.9		2133 (45.5)	723 (44.7)	288 (44.9)	340 (44.7)	782 (46.8)		
≥28		726 (15.5)	228 (14.1)	104 (16.2)	123 (16.2)	271 (16.2)		
Anti-diabetic Treatment (n,%)	4690						400.190	0.000
Non-insulin		1932 (41.2)	952 (58.9)	288 (44.9)**	272 (35.7)**	420 (25.1)**		
Insulin usage		2758 (58.8)	664 (41.1)	354 (55.1)	489 (64.3)	1251 (74.9)		
Adherence to exercise (n,%)	4156	2343 (56.4)	818 (57.3)	313 (54.8)	363 (53.4)	849 (57.5)	4.254	0.235
Adherence to diet (n,%)	3344	1825 (54.6)	654 (56.7)	249 (54.0)	294 (53.5)	628 (53.2)	3.354	0.340
Adherence to medication (n,%)	2765	2248 (81.3)	802 (83.0)	314 (80.9)	334 (77.0)**	798 (81.7)	7.395	0.060
Adherence to SMBG (n,%)	2759	1391 (50.4)	536 (55.1)	180 (46.5)**	198 (46.2)**	477 (49.1)**	14.817	0.002

Follow up characteristics									
Follow up≥24 months (n,%)	4690	2403 (51.2)	824 (51.0)	381 (59.3)**	382 (50.2)	816 (48.8)	21.129	0.000	
HbA <sub>1c</sub> measurements (number)	4690	4.00 (3.00, 6.00)	5.00 (3.00, 6.00)	6.00 (4.00, 7.00)	4.00 (3.00, 5.00)	4.00 (3.00, 6.00)	296.979	0.000	
HbA <sub>1c</sub> measurements /year (n,%)	4690						129.241	0.000	
<2		1291 (27.5)	417 (25.8)	96 (15.0)	262 (34.4)	516 (30.9)			
2~<3		1887 (40.3)	612 (37.9)	260 (40.5)	299 (39.3)	716 (42.8)			
≥3		1512 (32.2)	587 (36.3)	286 (44.5)	200 (26.3)	439 (26.3)			
Share-care (n,%)	4690	2420 (51.6)	720 (44.6)	358 (55.8)**	390 (51.2)**	952 (57.0)**	55.921	0.000	
Treatment change (n,%)	4690	2118 (45.2)	658 (40.7)	303 (47.2)**	341 (44.8)	816 (48.8)**	23.091	0.000	
Anti-diabetic Treatment (n,%)	4690						443.552	0.000	
Non-insulin		1957(41.7)	976(60.4)	292(45.5)**	276(36.3)**	413(24.7)**			
Insulin usage		2733(58.3)	640(39.6)	350(54.5)	485(63.7)	1258(75.3)			
Adherence to exercise (n,%)	3667	2534 (69.1) <sup>#</sup>	935 (75.6) <sup>#</sup>	365 (70.2) <sup>#</sup>	380 (67.6)** <sup>#</sup>	854 (63.4)** <sup>#</sup>	46.096	0.000	
Adherence to diet (n,%)	3208	2102 (65.5) <sup>#</sup>	840 (76.8) <sup>#</sup>	302 (65.8) <sup>#</sup> <sup>#</sup>	304 (61.4)** <sup>#</sup>	656 (56.6)**	106.438	0.000	
Adherence to medication (n,%)	3676	3375 (91.8) <sup>#</sup>	1182 (95.3) <sup>#</sup>	480 (92.3) <sup>#</sup>	515 (91.6)** <sup>#</sup>	1198 (88.5)** <sup>#</sup>	40.533	0.000	
Adherence to SMBG (n,%)	3661	2149 (58.7) <sup>#</sup>	828 (66.9) <sup>#</sup>	312 (59.8) <sup>#</sup> <sup>#</sup>	330 (59.0)** <sup>#</sup>	679 (50.6)**	70.813	0.000	

**Notes:** Data are numbers (%), medians (interquartile range (IQR)) or mean±standard deviation. Beginning with the second available HbA<sub>1c</sub> measure: Group 1: ≥90% of HbA<sub>1c</sub> measurements <7.5%; Group 2: 60–89% of HbA<sub>1c</sub> measurements <7.5%; Group 3: 30–59% of HbA<sub>1c</sub> measurements <7.5%; Group 4: <30% of HbA<sub>1c</sub> measurements <7.5%. Hypercholesterolemia: baseline cholesterol≥4.50 (mmol/L); High Triglyceridemia: baseline Triglyceride ≥1.70 (mmol/L). The proportion of cases in the whole. \*p<0.05 vs group 1; \*\*p<0.01 vs group 1; <sup>#</sup>p<0.01 follow up vs baseline.

**Abbreviations:** BMI, body mass index; CVD, cardiovascular disease; PAD, peripheral arterial disease; OAD, oral anti-diabetic drugs; DKD, diabetic kidney disease; HbA<sub>1c</sub>, haemoglobin A<sub>1c</sub>.





**Figure 1** Four HbA<sub>1c</sub> trajectories during the median of 2 years follow up in 4690 subjects with non-newly diagnosed Type 2 diabetes. Blue curve: group 1 with stable good glycaemic control; violet curve: group 2 with relative good glycaemic control; green curve: group 3 with moderate glycaemic control; red curve: group 4 with continuously poor glycaemic control.

subjects followed up for  $\geq 24$  months, and the median number of HbA<sub>1c</sub> measurements was 4 (IQR 3–6).

### HbA<sub>1c</sub> Trajectories

Based on the longitudinal HbA<sub>1c</sub> categories, we identified four patterns of HbA<sub>1c</sub> trajectories (Figure 1, Table 2). The subjects in Group 1 had stable, good HbA<sub>1c</sub> levels ( $n=1616$ , 34.5%) with a median baseline HbA<sub>1c</sub> of 6.6% and follow-up HbA<sub>1c</sub> measurements  $\leq 6.50\%$ . The subjects in Group 2 had relatively good HbA<sub>1c</sub> levels ( $n=642$ , 13.7%) with a median baseline HbA<sub>1c</sub> of 7.1% and follow-up HbA<sub>1c</sub> measurements  $\leq 7.20\%$ . The subjects in Group 3 had moderately controlled HbA<sub>1c</sub> levels ( $n=761$ , 16.2%) with a median baseline HbA<sub>1c</sub> of 7.7%, follow-up HbA<sub>1c</sub> measurements  $\leq 7.60\%$ , and 28.7% of subjects had an HbA<sub>1c</sub> change  $\geq -1.0\%$  from baseline to visit 1. The subjects in Group 4 had continuously poor HbA<sub>1c</sub> levels ( $n=1671$ , 35.6%) with a median baseline HbA<sub>1c</sub> of 8.7%, follow-up HbA<sub>1c</sub> measurements  $\leq 8.70\%$ , and 20.9% of subjects had an HbA<sub>1c</sub> change  $\geq -1.0\%$  from baseline to visit 1.

### Clinical Inertia

From Group 1 to Group 4, the diabetes duration and percentage of subjects having a diabetes duration  $\geq 10$  years and microvascular complications (retinopathy and DKD) increased gradually. Subjects in the three poorer control groups had a lower education level than those in Group 1.

From Group 1 to Group 4, the percentage of subjects treated with insulin at baseline (41.1%–74.9%) and during the follow-up period (39.6%–75.3%) increased gradually, while the percentage of subjects adhering to exercise, diet, medications and SMBG decreased gradually. In Group 1, 59.3% of subjects had unchanged treatment plans. Compared with the baseline, the adherence to exercise, diet, medications and SMBG improved significantly in the overall group and Group 1 to Group 3. Significantly improved adherence to exercise and medications was also found in Group 4. A higher proportion of subjects were managed with the share-care model (51.2%–57.0%) and had changed treatment plans (44.8%–48.8%) in the three poorer control groups than in Group 1. The highest

**Table 2** HbA<sub>1c</sub> Value and Number of Measurements for the Overall Study Population and for the 4 Groups with Different Cumulative Glycaemic Exposures

Visit of Follow Up	n	Overall	Group 1	Group 2	Group 3	Group 4	$\chi^2$	P
Baseline	4690	7.50 (6.60, 8.80)	6.60 (6.20, 7.20)	7.10 (6.60, 7.80)**	7.70 (7.10, 8.90)**	8.70 (7.80, 9.80)**	1761.711	0.000
<7.50		2249(48.0)	1295(80.1)	403(62.8)**	303(39.8)**	248(14.8)**	1544.591	0.000
7.50~8.90		1347(28.7)	221(13.7)	156(24.3)	278(36.5)	692(41.4)		
≥9.00		1094(23.3)	100(6.2)	83(12.9)	180(23.7)	731(43.7)		
Visit 1	4357	7.30 (6.50, 8.40)	6.40 (6.00, 6.80)	7.00 (6.50, 7.40)**	7.40 (7.00, 8.00)**	8.60 (7.90, 9.60)**	2833.385	0.000
Change from baseline to visit 1	4357	-0.10 (-0.80, 0.40)	-0.20 (-0.60, 0.10)	-0.20 (-0.90, 0.30)	-0.20 (-1.10, 0.40)	0.00 (-0.80, 0.80)**	80.194	0.000
<-0.5%	4357	2838 (65.1)	986 (67.4)	383 (64.2)	415 (57.2)**	1054 (67.1)	34.048	0.000
-0.9~-0.5%		573 (13.2)	201 (13.7)	81 (13.6)	103 (14.2)	188 (12.0)		
≥-1.0%		946 (21.7)	276 (18.9)	133 (22.3)	208 (28.7)	329 (20.9)		
Visit 2	4420	7.30 (6.53, 8.40)	6.45 (6.10, 6.80)	7.00 (6.60, 7.40)**	7.50 (7.00, 8.10)**	8.60 (8.00, 9.70)**	2911.657	0.000
Visit 3	3328	7.20 (6.50, 8.30)	6.40 (6.00, 6.80)	7.00 (6.60, 7.50)**	7.50 (7.10, 8.10)**	8.60 (8.00, 9.60)**	2248.103	0.000
Visit 4	2408	7.20 (6.50, 8.20)	6.50 (6.10, 6.80)	7.10 (6.70, 7.50)**	7.50 (7.10, 8.00)**	8.60 (7.90, 9.50)**	1586.085	0.000
Visit 5	1570	7.20 (6.50, 8.20)	6.50 (6.10, 6.70)	7.10 (6.70, 7.50)**	7.60 (7.23, 8.00)**	8.60 (8.00, 9.30)**	1041.278	0.000
Visit 6	967	7.10 (6.50, 7.90)	6.40 (6.00, 6.73)	7.10 (6.80, 7.50)**	7.50 (7.10, 8.20)**	8.60 (7.90, 9.20)**	633.442	0.000
Last visit	4690	7.40 (6.60, 8.50)	6.50 (6.10, 6.80)	7.20 (6.70, 7.60)**	7.60 (7.10, 8.20)**	8.70 (8.00, 9.70)**	3114.141	0.000

**Notes:** Data are numbers (%), medians (interquartile range (IQR)). Beginning with the second available HbA<sub>1c</sub> measure: Group 1: ≥90% of HbA<sub>1c</sub> measurements <7.5%; Group 2: 60~89% of HbA<sub>1c</sub> measurements <7.5%; Group 3: 30~59% of HbA<sub>1c</sub> measurements <7.5%, and Group 4: <30% of HbA<sub>1c</sub> measurements <7.5%. \*\* p<0.01 vs group 1.

proportion of subjects being followed up  $\geq 24$  months (59.3%) and having HbA<sub>1c</sub> measurements  $\geq 3$  times (44.5%) per year was found in Group 2. Compared with Group 1, only 26.3% of subjects checked HbA<sub>1c</sub>  $\geq 3$  times per year in Group 3 and Group 4. (Table 1).

## Multinomial Logistic Regression Analysis

Factors related to clinical inertia shown as insulin treatment, treatment change, poor adherence to diet, exercise, SMBG during the follow-up period and  $< 3$  HbA<sub>1c</sub> measurements per year were still significant after multivariable adjustment. Diabetic retinopathy, baseline HbA<sub>1c</sub>  $\geq 7.5\%$ , insulin treatment and poor adherence to diet during the follow-up period were associated with a higher chance of belonging to the three groups with poorer glycaemic control; while HbA<sub>1c</sub> change  $\geq -0.5\%$  from baseline to visit 1 was associated with a lower chance of belonging to these three groups (reference group: Group 1; Table 3). Treatment change and  $< 3$  HbA<sub>1c</sub> measurements per year were associated with a higher chance of belonging to Group 3 or Group 4. Poor adherence to exercise and SMBG were additional factors associated with a higher chance of belonging to Group 4. Education below high school level and poor adherence to SMBG during the follow-up period were associated with a higher chance of belonging to Group 2.

## Discussion

This longitudinal retrospective study identified four distinct HbA<sub>1c</sub> trajectories in people with non-newly diagnosed type 2 diabetes in Chinese primary care with two years of serial HbA<sub>1c</sub> measurements. After management, 48.2% of the study population with median age of 61.75 years and median diabetes duration of 9.58 years demonstrated good glycaemic control, with 34.5% shown as good, stable control and 13.7% as relatively good control. Although 16.2% of the participants exhibited moderate control and 35.6% exhibited poor control, 28.7% and 20.9% of them respectively had an HbA<sub>1c</sub> decrease  $\geq -1.0\%$  from the baseline during the follow-up period. This proportion of people attaining good glycaemic control was much lower than that in previous studies of patients with newly diagnosed type 2 diabetes and indicated the difficulty of long-term glycaemic control.<sup>3–5</sup> Higher HbA<sub>1c</sub> measurements at one year were associated with higher baseline HbA<sub>1c</sub>, higher body weight and low treatment adherence.<sup>16</sup> Long diabetes duration was a risk factor for poor glycaemic control and increased the

difficulty of reaching the HbA<sub>1c</sub> target. Distinct HbA<sub>1c</sub> trajectories in non-newly diagnosed type 2 diabetes have only been reported in one Israeli study,<sup>6</sup> in which the largest group (53.2%) showed persistently good glycaemic control with a mean HbA<sub>1c</sub> of 7.1%, which was similar to that in our study, and a mean duration of 60.8 months, which was much shorter than in our study.

These results show that clinical inertia exists for glycaemic control. Patients would benefit from early good glycaemic control and be inclined to develop long-term stable, good HbA<sub>1c</sub> trajectory thereafter.<sup>3–7</sup> Severe hyperglycaemia could be decreased to the level of good glycaemic control within one year and then kept stable for the subsequent four years.<sup>4</sup> In this present analysis, the change of the percentage of subjects having a HbA<sub>1c</sub>  $\geq 7.50\%$  decreased. Therefore, although baseline HbA<sub>1c</sub>  $\geq 7.5\%$  was associated with a higher chance of belonging to the poorer glycaemic control groups, an HbA<sub>1c</sub> change  $\geq -0.5\%$  from baseline to visit 1, especially  $\geq -1.0\%$ , was associated with a significantly lower chance of belonging to the poorer glycaemic control groups. This indicated that to attain long-term, good, stable glycaemic control, subjects with poor glycaemic control should be managed to reduce their HbA<sub>1c</sub> levels to a certain extent by the follow-up visit after registration.

We found significantly more participants were treated with insulin and managed with the share-care model in the three poorer glycaemic control groups. The proportion of patients treated with insulin, managed with the share-care model and had treatment changes in the stable, good group was significantly lower than that in the poorest control group. After multivariable adjustment, insulin treatment and treatment change were still associated with a higher chance of belonging to the two poorest control groups, indicating that intensified management of glycaemic control already existed. The results were similar to Luo's study.<sup>5</sup> Ordinary people often have no awareness of diabetes and think that they do not have it, which leads them to ignore the disease and makes it more difficult to manage.<sup>17</sup> Appropriate treatment titration and adherence to medications and self-management behaviour were two important factors related to glycaemic control and clinical inertia. Medications, especially insulin treatment, were associated with glycaemic change from severe hyperglycaemia to good glycaemic control.<sup>4</sup> That is the reason why insulin treatment was most prevalent in the groups with poorer control, and the addition of multiple insulin



**Table 3** Multinomial Logistic Regression Analysis Results for the 3 Groups with Less Good HbA<sub>1c</sub> Control

Variables	Group 2		Group 3		Group 4	
	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)
Diabetes duration (≥10 vs <10 years)	0.239	1.171 (0.900~1.523)	0.143	1.224 (0.934~1.604)	0.175	1.198 (0.923~1.555)
Education (below vs above high school)	0.002	1.514 (1.162~1.972)	0.097	1.258 (0.960~1.649)	0.226	1.175 (0.905~1.526)
Hypertension (yes vs no)	0.546	1.085 (0.832~1.416)	0.151	1.226 (0.929~1.619)	0.599	0.931 (0.713~1.215)
Retinopathy (yes vs no)	0.025	1.513 (1.052~2.175)	0.005	1.692 (1.171~2.445)	0.000	1.946 (1.367~2.770)
DKD (yes vs no)	0.769	1.067 (0.693~1.641)	0.252	1.282 (0.838~1.961)	0.543	1.137 (0.751~1.722)
Neuropathy (yes vs no)	0.803	0.967 (0.742~1.260)	0.247	0.850 (0.646~1.119)	0.200	1.190 (0.912~1.553)
BMI: no overweight/obesity		Reference		Reference		Reference
Overweight	0.914	1.023 (0.677~1.545)	0.962	0.990 (0.653~1.500)	0.450	1.168 (0.781~1.746)
Obesity	0.475	1.105 (0.840~1.455)	0.782	0.960 (0.721~1.279)	0.525	1.094 (0.829~1.445)
Baseline HbA <sub>1c</sub> (%)≤7.40		Reference		Reference		Reference
7.50~8.90	0.000	4.174 (2.752~6.331)	0.000	15.498 (10.244~23.445)	0.000	61.433 (41.034~91.973)
≥9.0	0.000	4.012 (2.099~7.669)	0.000	32.001 (17.504~58.505)	0.000	618.859 (337.237~1135.658)
HbA <sub>1c</sub> change from baseline to visit 1 (<-0.5%)						
-0.9~-0.5%	0.045	0.661 (0.441~0.991)	Reference	0.443 (0.284~0.693)	Reference	0.156 (0.100~0.244)
≥-1.0%	0.000	0.370 (0.222~0.617)	0.000	0.181 (0.109~0.301)	0.000	0.022 (0.013~0.037)
Insulin usage (yes vs no)	0.000	1.909 (1.463~2.492)	0.000	2.297 (1.738~3.036)	0.000	2.901 (2.210~3.808)
Share-care (yes vs no)	0.204	1.191 (0.909~1.560)	0.379	0.882 (0.667~1.167)	0.178	0.830 (0.633~1.089)
Treatment adjustment (yes vs no)	0.435	1.108 (0.856~1.435)	0.029	1.348 (1.030~1.764)	0.024	1.348 (1.039~1.748)
Poor adherence to exercise (yes vs no)	0.410	1.142 (0.832~1.567)	0.301	1.187 (0.858~1.642)	0.036	1.392 (1.021~1.897)
Poor adherence to diet (yes vs no)	0.002	1.610 (1.187~2.184)	0.000	2.165 (1.589~2.951)	0.000	1.992 (1.476~2.688)
Poor adherence to medication (yes vs no)	0.897	1.036 (0.611~1.756)	0.357	0.769 (0.439~1.346)	0.996	1.001 (0.600~1.671)
Poor adherence to SMBG (yes vs no)	0.029	1.402 (1.035~1.900)	0.138	1.270 (0.926~1.740)	0.000	1.772 (1.309~2.398)
HbA <sub>1c</sub> measurements (<3 vs ≥3 per year)	0.037	0.762 (0.589~0.984)	0.002	1.551 (1.176~2.044)	0.002	1.530 (1.174~1.996)

**Abbreviations:** DKD, diabetic kidney disease; BMI, body mass index; % HbA<sub>1c</sub>, haemoglobin A<sub>1c</sub>.

injections was the most common intensification.<sup>5</sup> In the present analysis, a lack of change in antidiabetic treatment during the follow-up period was taken as clinical inertia originating from healthcare professionals; and poor adherence to healthy diet, activity, SMBG and medications during the follow-up period was taken as clinical inertia originating from patients.

Some patients still had poor glycaemic control despite being treated with insulin and having changes in treatment. Nonresponse or nonadherence were accepted as the important risk factors. The improved HbA<sub>1c</sub> control was usually found accompanied by significantly increased self-care behaviour adherence scores of healthy diet, physical activity and SMBG.<sup>18,19</sup> Exercise can improve insulin resistance and HbA<sub>1c</sub> control, given enough intensity and time.<sup>20,21</sup> SMBG is a necessary means of diabetes management, and with effective communication between healthcare professionals and patients, SMBG can become an effective diabetes self-management tool.<sup>22</sup> The SMBG schema could be adopted and reviewed before proceeding to the next therapeutic drug step.<sup>23</sup>

We demonstrated the importance of adherence to diabetes self-management behaviours in this analysis. Compared with the baseline, adherence to exercise, diet, medications and SMBG improved significantly. After multivariable adjustment, poor adherence to diet, exercise and SMBG were still significant risk factors for poor glycaemic control. The importance of adherence to diet was persistently significant for all poor control groups, even after multivariable adjustment. The proportion of subjects being adherent to diet increased during the follow-up period for participants overall, and increased from the poorest control group to the stable, good control group, which was similar to Salinero-Fort's report (55.7%–74.2%).<sup>24</sup> With intensified management, free medications, free visits with clinicians, aggressive titration of medications and >90% adherence to medications, 68.2% of participants with a mean diabetes duration >10 years reached the target of HbA<sub>1c</sub> <8.0% in the standard glycaemia therapy group of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.<sup>25</sup> In this study, 64.4% of subjects with a median diabetes duration of 9.58 years had ≥30% of HbA<sub>1c</sub> measurements <7.5% during all follow-up periods, with a median HbA<sub>1c</sub> of <6.50% in Group 1, <7.20% in Group 2 and <7.60% in Group 3, which demonstrated a similar glycaemic control to the ACCORD trial. The present study also demonstrated the possibility of practical intensified management, treatment titration and adherence to self-management behaviours in the real world.

Regularity of measuring HbA<sub>1c</sub> is another factor related to clinical inertia. Both the frequency of HbA<sub>1c</sub> measurements and the frequency of medication intensification were associated with a higher chance of reaching the HbA<sub>1c</sub> target.<sup>26</sup> The greatest annual change of HbA<sub>1c</sub> occurred between 6 months and 2 years after diagnosis over 10 years of follow-up in a UK study.<sup>27</sup> More frequent monitoring of HbA<sub>1c</sub> and adjustment of glucose-lowering drugs may be essential to prevent the decline of glycaemic control. Low frequency of testing and over-testing of HbA<sub>1c</sub> in people with type 2 diabetes was commonly found in primary care. In the present analysis, the percentage of overall participants who had a frequency of HbA<sub>1c</sub> measurements ≥2 and ≥3 per year were 72.5% and 32.2%, respectively, similar to that of a German study (74% ≥2 per year).<sup>28</sup> According to international guidance, ≥3 HbA<sub>1c</sub> tests per year among adults with controlled type 2 diabetes might be over-testing; one test per year was associated with lower likelihoods of achieving the HbA<sub>1c</sub> target.<sup>29,30</sup> The optimal HbA<sub>1c</sub> testing frequency required to maximise the downward trajectory in HbA<sub>1c</sub> was found to be four times per year, particularly in those with suboptimal HbA<sub>1c</sub> and initial HbA<sub>1c</sub> of ≥7%.<sup>31</sup> In the present analysis, the percentage of participants who had ≥3 HbA<sub>1c</sub> measurements per year was significantly higher than that in Group 3 and Group 4, and <3 HbA<sub>1c</sub> measurements per year was a significant risk factor for belonging to poorer glycaemic control groups. These findings provided objective evidence that a low HbA<sub>1c</sub> monitoring frequency was associated with a significant detrimental effect on diabetes control. The importance of HbA<sub>1c</sub> monitoring frequency needs to be further emphasised in diabetes management.

A strength of the present study is the large number of people with non-newly diagnosed type 2 diabetes in Chinese primary care. Our study has several limitations. First, this was a multi-centre study, and HbA<sub>1c</sub> was not measured in the same central laboratory. Second, the limitation of using the percentage of HbA<sub>1c</sub> measurements <7.5% to categorise HbA<sub>1c</sub> trajectories is worth noting. It is a simplified reflection of the longitudinal HbA<sub>1c</sub> profiles showing an aspect in general. However, individual HbA<sub>1c</sub> trajectories may be much more diverse and complicated, and the model may not be able to capture all these different individual patterns. Third, the analysis of medication in this study was based on patients' medication records registered on the share-care information system rather than being imported from prescribed medication records and was incomplete. The dose change of medications was not considered, and there may be an underestimation of the

treatment change effect. Fourth, although the information on diet, exercise, medication and SMBG was collected according to the Chinese version of the diabetes self-care behaviour scale, the definition of good compliance was adjusted and simplified. Fifth, because of the long study period, patients did not pay enough attention to follow-up procedures and some subjects were lost. Finally, information on complications and comorbidities was assessed based on self-reported history and records of physician diagnosis at the time of recruitment, and therefore may not be accurate, though this was usual practice.

In conclusion, four distinct patterns of longitudinal HbA<sub>1c</sub> trajectories were identified in participants with non-newly diagnosed type 2 diabetes using the percentage of HbA<sub>1c</sub> measurements <7.5% in Chinese primary care with two years of serial HbA<sub>1c</sub> measurements. Approximately half of the participants showed good glycaemic control. The intensified management, treatment titration and improved adherence to self-management behaviours in the real world are practical. Despite a higher percentage of subjects being treated with insulin in the poorer control groups, the percentage of subjects being adherent to exercise, diet, medications and SMBG was lower, together with a lower frequency of HbA<sub>1c</sub> tests per year. Aggressive treatment changes, good adherence during the follow-up period,  $\geq 3$  HbA<sub>1c</sub> measurements per year and reducing the HbA<sub>1c</sub> level to a certain extent by the first follow-up visit are important for good, stable, long-term glycaemic control.

## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

Beijing Fengtai District Health System Project Approval 2017-81.

## Disclosure

The authors declare that there is no conflict of interest associated with this manuscript.

## References

1. Luo M, Tan KHX, Tan CS, Lim WY, Tai ES, Venkataraman K. Longitudinal trends in HbA<sub>1c</sub> patterns and association with outcomes: a systematic review. *Diabetes Metab Res Rev*. 2018;34(6):e3015. doi:10.1002/dmrr.3015
2. Lacy ME, Gilsanz P, Karter AJ, Quesenberry CP, Pletcher MJ, Whitmer RA. Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes. *Diabetes Care*. 2018;41(11):2339–2345. doi:10.2337/dc18-0073
3. Laiteerapong N, Karter AJ, Moffet HH, et al. Ten-year hemoglobin A<sub>1c</sub> trajectories and outcomes in type 2 diabetes mellitus: the Diabetes & Aging Study. *J Diabetes Complications*. 2017;31(1):94–100. doi:10.1016/j.jdiacomp.2016.07.023
4. Rathmann W, Schwandt A, Hermann JM, et al. DPV Initiative. Distinct trajectories of HbA<sub>1c</sub> in newly diagnosed Type 2 diabetes from the DPV registry using a longitudinal group-based modelling approach. *Diabet Med*. 2019;36(11):1468–1477. doi:10.1111/dme.14103
5. Luo M, Tan CS, Lim WY, et al. Association of diabetes treatment with long-term glycemic patterns in patients with type 2 diabetes mellitus: a prospective cohort study. *Diabetes Metab Res Rev*. 2019;35(4):e3122. doi:10.1002/dmrr.3122
6. Karpati T, Leventer-Roberts M, Feldman B, Cohen-Stavi C, Raz I, Balicer R. Patient clusters based on HbA<sub>1c</sub> trajectories: a step toward individualized medicine in type 2 diabetes. *PLoS One*. 2018;13(11):e0207096. doi:10.1371/journal.pone.0207096
7. McCoy RG, Ngufo C, Van Houten HK, Caffo B, Shah ND. Trajectories of Glycemic Change in a National Cohort of Adults With Previously Controlled Type 2 Diabetes. *Med Care*. 2017;55(11):956–964. doi:10.1097/MLR.0000000000000807
8. Rozing MP, Möller A, Aabenhus R, Siersma V, Rasmussen K, Køster-Rasmussen R. Changes in HbA<sub>1c</sub> during the first six years after the diagnosis of Type 2 diabetes mellitus predict long-term microvascular outcomes. *PLoS One*. 2019;14(11):e0225230. doi:10.1371/journal.pone.0225230
9. Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. *Diabetes Obes Metab*. 2018;20(2):427–437. doi:10.1111/dom.13088
10. Andreozzi F, Candido R, Corrao S, et al. Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. *Diabetol Metab Syndr*. 2020;7(12):52. doi:10.1186/s13098-020-00559-7
11. Chen YY, Peng MG. The validity and reliability of a Chinese version of the diabetes self-care activities questionnaire. *Chine J Practical Nursing*. 2011;27(14):60–62.
12. American Diabetes Association; European Association for the Study of Diabetes; International Federation of Clinical Chemistry and Laboratory Medicine; International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA<sub>1c</sub> measurement. *Diabetologia*. 2007;50:2042–2043. doi:10.1007/s00125-007-0789-7
13. Looker HC, Nyangoma SO, Cromie D, et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. *Diabetologia*. 2012;55(9):2335–2342. doi:10.1007/s00125-012-2596-z. Epub 2012 Jun 12. PMID: 22688348; PMCID: PMC3411303.
14. McGrath K, Edi R. Diabetic Kidney Disease: diagnosis, Treatment, and Prevention. *Am Fam Physician*. 2019;99(12):751–759. PMID: 31194487.
15. Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. *Lancet Diabetes Endocrinol*. 2019;7(12):938–948. doi:10.1016/S2213-8587(19)30081-6. Epub 2019 Oct 14. PMID: 31624024.
16. Pathiraja NP, Colman PG, Wentworth JM. Glycaemic trajectory and predictors of suboptimal glycaemic control in people with type 2 diabetes. *Intern Med J*. 2020;50(11):1415–1418. doi:10.1111/imj.15059. PMID: 33215839.

17. Cicero AFG, Fogacci F, Tocci G, et al. Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: data from the Brisighella Heart Study. *Nutr Metab Cardiovasc Dis.* 2020;30(6):907–914. doi:10.1016/j.numecd.2020.03.005. Epub 2020 Mar 16. PMID: 32249143.
18. Ji H, Chen R, Huang Y, Li WQ, Shi CH, Zhou J. Effect of simulation education and case management on glycemic control in type 2 diabetes. *Diabetes Metab Res Rev.* 2019;35(3):e3112. doi:10.1002/dmrr.3112
19. Weinstock RS, Braffett BH, McGuigan P, et al.; TODAY Study Group. Self-Monitoring of Blood Glucose in Youth-Onset Type 2 Diabetes: results From the TODAY Study. *Diabetes Care.* 2019;42(5):903–909. doi:10.2337/dc18-1854.
20. Balducci S, D'Errico V, Haxhi J, et al. Italian Diabetes and Exercise Study 2 (IDES- 2) Investigators. Effect of a Behavioral Intervention Strategy for Adoption and Maintenance of a Physically Active Lifestyle: the Italian Diabetes and Exercise Study 2 (IDES\_2): a Randomized Controlled Trial. *Diabetes Care.* 2017;40(11):1444–1452. doi:10.2337/dc17-0594
21. Fayehun AF, Olowookere OO, Ogunbode AM, Adetunji AA, Esan A. Walking prescription of 10 000 steps per day in patients with type 2 diabetes mellitus: a randomised trial in Nigerian general practice [J]. *Br J Gen Pract.* 2018;68(667):e139–e145. doi:10.3399/bjgp18X694613
22. Chinese Diabetes Society. Chinese guideline for clinical application of blood glucose monitoring (2015 Edition). *Chin J Diabetes Mellitus.* 2015;7(10):603–613.
23. Madeo B, Diazz C, Granata ARM, et al. Effect of a standard schema of self-monitoring blood glucose in patients with poorly controlled, non-insulin-treated type 2 diabetes mellitus: a controlled longitudinal study. *J Popul Ther Clin Pharmacol.* 2020;27(S Pt 2):e1–e11. doi:10.15586/jptcp.v27iSP2.680. PMID: 32757545.
24. Salinero-Fort MA, Carrillo-de E, Arrieta-Blanco FJ, et al. Effectiveness of PRECEDE model for health education on changes and level of control of HbA1c, blood pressure, lipids, and body mass index in patients with type 2 diabetes mellitus. *BMC Public Health.* 2011;11:267. doi:10.1186/1471-2458-11-267
25. Drake TC, Hsu FC, Hire D, et al. Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Diabetes Obes Metab.* 2016;18(1):92–95.
26. Turchin A, Goldberg SI, Breydo E, Shubina M, Einbinder JS. Copy/paste documentation of lifestyle counseling and glycemic control in patients with diabetes: true to form? *Arch Intern Med.* 2011;171:1393–1394. doi:10.1001/archinternmed.2011.219
27. Lind M, Pivodic A, Cea-Soriano L, Nerman O, Pehrsson NG, Garcia-Rodriguez LA. Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK. *Diabetologia.* 2014;57(8):1586–1594. doi:10.1007/s00125-014-3250-8
28. Kostev K, Jacob L, Lucas A, Rathmann W. Low annual frequency of HbA (1c) testing in people with Type 2 diabetes in primary care practices in Germany. *Diabet Med.* 2018;35(2):249–254. doi:10.1111/dme.13556
29. McCoy RG, Van Houten HK, Ross JS, Caffo B, Shah ND. HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001–13: observational population based study. *BMJ.* 2015;351:h6138. doi:10.1136/bmj.h6138
30. Duff CJ, Solis-Trapala I, Driskell OJ, et al. The frequency of testing for glycated haemoglobin, HbA1c, is linked to the probability of achieving target levels in patients with suboptimally controlled diabetes mellitus. *Clin Chem Lab Med.* 2018;57(2):296–304. doi:10.1515/cclm-2018-0503
31. Driskell OJ, Holland D, Waldron JL, et al. Reduced testing frequency for glycated hemoglobin, HbA1c, is associated with deteriorating diabetes control. *Diabetes Care.* 2014;37(10):2731–2737. doi:10.2337/dc14-0297

## Patient Preference and Adherence

Dovepress

### Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal that focusing on the growing importance of patient preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease

states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/patient-preference-and-adherence-journal>